Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2019

01-06-2019 | Hepatitis C | Hepatitis C (H Vargas and S Flamm, Section Editors)

HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?

Authors: Javier Crespo, Susana Llerena, Carmen Cobo, Joaquin Cabezas, Antonio Cuadrado

Published in: Current Hepatology Reports | Issue 2/2019

Login to get access

Abstract

Purpose of Review

In this review, the peculiarities of infection and treatment of HCV in the prison population are detailed. In addition, the barriers to HCV treatment and possible solutions are highlighted.

Recent Findings

Several previous experiences of HCV treatment in prisons have been successful. In this manuscript, we detail the most relevant.

Summary

We think that incarceration should be considered an opportunity to engage this population in health care. Therefore, we should encourage systematic screening of these patients and promote the access to treatment by supporting equity with the general population. Thus, inmates’ care must involve a multidisciplinary team. To solve this matter, we propose telehealth to bring together all these services and overcome the geographical barrier(s) and improve costs. Then, to go further in hepatitis C elimination, harm-reduction programs should be added to treat with direct-acting antivirals.
Literature
1.
2.
Cuadrado A, Perelló C, Llerena S, Gómez M, Escudero MD, Rodriguez L, et al. Estudio de la prevalencia de la Hepatitis C en la población española. Estudio PREVHEP / Cohorte ETHON. Gastroenterol Hepatol. 2107;40(Suppl E1):1.
3.
Rodriguez-Tajes S, Dacal Y, Collazos C, Frías MC, Vidal Benede MJ, Jané M, et al. Estudio de prevalencia por los virus de la hepatitis B y C en Cataluña. Gastroenterol Hepatol. 2017;40(Suppl. E1):13.
4.
Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep. 2014;129(2):187–95.CrossRefPubMedPubMedCentral
5.
Sterling RK, Cherian R, Lewis S, Genther K, Driscoll C, Martin K, et al. Treatment of HCV in the department of corrections in the era of oral medications. J Correct Health Care. 2018;24(2):127–36.CrossRefPubMed
6.
Saiz de la Hoya P, Marco A, Garcia-Guerrero J, Rivera A. Prevalhep study g. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011;30(7):857–62.CrossRefPubMed
7.
Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study. J Viral Hepat. 2017;24(9):733–41.CrossRefPubMed
8.
9.
10.
Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health. 2006;120(1):33–41.CrossRefPubMed
11.
Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427–80.CrossRefPubMedPubMedCentral
12.
Binswanger IA, Krueger PM, Steiner JF. Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population. J Epidemiol Community Health. 2009;63(11):912–9.CrossRef
13.
Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102.CrossRefPubMed
14.
Baillargeon J, Black SA, Leach CT, Jenson H, Pulvino J, Bradshaw P, et al. The infectious disease profile of Texas prison inmates. Prev Med. 2004;38(5):607–12.CrossRefPubMed
15.
Piselli M, Attademo L, Garinella R, Rella A, Antinarelli S, Tamantini A, et al. Psychiatric needs of male prison inmates in Italy. Int J Law Psychiatry. 2015;41:82–8.CrossRefPubMed
16.
Piselli M, Elisei S, Murgia N, Quartesan R, Abram KM. Co-occurring psychiatric and substance use disorders among male detainees in Italy. Int J Law Psychiatry. 2009;32(2):101–7.CrossRefPubMed
17.
Esposito M. The health of Italian prison inmates today: a critical approach. J Correct Health Care. 2010;16(3):230–8.CrossRefPubMed
18.
19.
Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323–30.CrossRefPubMedPubMedCentral
20.
21.
22.
•• Vroling H, Oordt-Speets AM, Madeddu G, Babudieri S, Monarca R, O’Moore E, et al. A systematic review on models of care effectiveness and barriers to hepatitis C treatment in prison settings in the EU/EEA. J Viral Hepat. 2018;25(12):1406–22. https://​doi.​org/​10.​1111/​jvh.​12998 Complete and updated review in hepatitis C management in prison.CrossRefPubMed
23.
Redman JS, Sterling RK. Treating HCV in a captive audience: eradication efforts in the prison microenvironment. Am J Gastroenterol. 2018;113(11):1585–7.CrossRefPubMed
24.
Juan J, de la Hoya PS, Marco A, Anton JJ, Faraco I, Yllobre C, et al. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study). Eur J Gastroenterol Hepatol. 2014;26(10):1083–9.CrossRefPubMed
25.
Marco A. Tasa y causas de discontinuación del tratamiento con Interferón Pegilado (INFpeg) más Ribavirina (RBV) en presos tratados de HCC en Cataluña durante 2002-2008. Revista Española de Sanidad Penitenciaria. 2010;S12.
26.
Marco A. Respuesta virológica rápida extendida en presos españoles con y sin infección por vih tratados de la hepatitis crónica C con Telaprevir, Peginterferon Alfa y Ribavirina. Revista Española de Sanidad Penitenciaria. 2014;S16.
27.
Marco A. 18 meses de tratamiento con Telaprevir o Boceprevir más Interferon Pegilado y Ribavirina en presos de Cataluña. Resultados preliminares de eficacia y de discontinuación de tratamiento. Revista espanola de sanidad penitenciaria. 2014;S16.
28.
Marco-Mouriño A, Espinosa M, Jordá M, Amado E, Troncoso A, Turu E, et al. Interrupción del tratamiento de la hepatitis C crónica con antivirales de acción directa por causas de origen penitenciario en las prisiones de Cataluña. Revista espanola de sanidad penitenciaria. 2016;(S18):88.
29.
Saiz de la Hoya P, Marco A, García-Guerrero J, Faraco I, Antón J, Portilla J, et al. Estudio comparativo de la eficacia en población presa con hepatitis crónica C del tratamiento directamente observado de Ribavirina vs autoadministrado, ambos con Interferón Pegilado alfa2a directamente observado (ensayo clínico Ribadot). Revista espanola de sanidad penitenciaria. 2010(S12):2.
30.
Touzón-López C, Solé C, Gallego C, Almada G, Rodríguez L, Valls I, et al. Eficacia, seguridad y discontinuación del tratamiento de la Hepatitis C Crónica con antivirales de acción directa en las prisiones de Cataluña. Revista espanola de sanidad penitenciaria. 2016;Sup. 18:87.
31.
Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187–90.CrossRefPubMed
32.
Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust. 2010;192(9):496–500.PubMed
33.
de Juan J, Faraco I, Saiz de la Hoya P, Marco A, Yllobre C, Da Silva A, et al. Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study. Rev Esp Sanid Penit. 2011;13(2):44–51.PubMed
34.
Farley JD, Wong VK, Chung HV, Lim E, Walters G, Farley TA, et al. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol. 2005;19(3):153–6.CrossRefPubMed
35.
Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, et al. HCV infected prisoners: should they be still considered a difficult to treat population? BMC Infect Dis. 2013;13:374.CrossRefPubMedPubMedCentral
36.
Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis. 2013;56(8):1078–84.CrossRefPubMed
37.
Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47(7):952–61.CrossRefPubMedPubMedCentral
38.
Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, et al. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology. 2012;56(4):1252–60.CrossRefPubMedPubMedCentral
39.
Saiz de la Hoya P, Portilla J, Marco A, Garcia-Guerrero J, Faraco I, Anton J, et al. Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting. Gastroenterol Hepatol. 2014;37(8):443–51.CrossRefPubMed
40.
Simonovic Babic J, Bojovic K, Delic D, Katanic N, Mitrovic N, Malinic J. Antiviral treatment of hepatitis C in Serbian prison setting: medical treatment outcomes and patients’ adherence. Med Pregl. 2016;69(3–4):85–91.CrossRefPubMed
41.
Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig Dis Sci. 2009;54(6):1325–30.CrossRefPubMed
42.
• Kronfli N, Linthwaite B, Kouyoumdjian F, Klein MB, Lebouche B, Sebastiani G, et al. Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: a systematic review. Int J Drug Policy. 2018;57:95–103. https://​doi.​org/​10.​1016/​j.​drugpo.​2018.​04.​003 Updated systematic review of hepatitis C treatment and linkage to care in prison.CrossRefPubMed
43.
44.
Yap L, Carruthers S, Thompson S, Cheng W, Jones J, Simpson P, et al. A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One. 2014;9(2):e87564.CrossRefPubMedPubMedCentral
45.
46.
European Monitoring Centre for Drugs and Drag Addiction. Health and social responses to drug problems: a European guide: Publicantion Office of the European Union; 2017.
47.
Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112(7):1302–14.CrossRefPubMedPubMedCentral
48.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRef
49.
Foschi A, Casana M, Radice A, Ranieri R, d’Arminio Monforte A. Hepatitis C management in prisons: an insight into daily clinical practice in three major Italian correctional houses. Hepatology. 2016;64(5):1821–2.CrossRefPubMed
50.
51.
•• Cuadrado A, Llerena S, Cobo C, Pallas JR, Mateo M, Cabezas J, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol 2018;113(11):1639–1648. https://​doi.​org/​10.​1038/​s41395-018-0157-x. Spanish model to attend inmates in managing hepatitis C infection with a test-and-treat strategy supported by a telemedicine tool and multidisciplinary team..
52.
Fernández-González F, Matilla-Peña A, Gijón-Vidaurreta P, Rincón-Rodríguez D, Reigadas-Ramirez E, Clemente-Ricote G. Tratamiento con Sofosbuvir Ledipasvir en población penitenciaria española con Hepatitis crónica C. Revista Epañola de Sanidad Penitenciaria. 2016;18(Suplemento XI Congreso Nacional y XIX Jornadas de la Sociedad Española de Sanidad Penitenciaria):99.
53.
Jiménez-Galán G, Alía C, Fernández C, Velasco M, Pérez E, Montero L. Efectividad y seguridad del tratamiento con antivirales de acción directa (AAD) y su impacto en la rigidez hepática en pacientes con hepatitis crónica VHC. Experiencia en un Centro Penitenciario. Revista Epañola de Sanidad Penitenciaria. 2016;18(Suplemento XI Congreso Nacional y XIX Jornadas de la Sociedad Española de Sanidad Penitenciaria):92.
54.
Mínguez-Gallego C, Jorge-Vidal V, Serrano-Balaguer M, Vera-Remartinez E, Herrero-Matías A, García-Guerrero J. Eficacia de las terapias libres de interferón frente al VHC en el medio penitenciario. Revista Epañola de Sanidad Penitenciaria. 2016;Sup. 18(Suplemento XI Congreso Nacional y XIX Jornadas de la Sociedad Española de Sanidad Penitenciaria):96.
55.
• Marco A, Roget M, Cervantes M, Forne M, Planella R, Miquel M, et al. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat. 2018;25(11):1280–6. https://​doi.​org/​10.​1111/​jvh.​12940 Treatment hepatitis C in prison is similar to the general population in terms of efficacy.CrossRefPubMed
56.
Chhatwal JLK, He T, Roberts M, Ayer T, Samur S, et al. Hepatitis C treatment in United States prisons prevents transmission and is cost- saving for the society: AASLD; 2016.
57.
Ndeffo-Mbah ML, Vigliotti VS, Skrip LA, Dolan K, Galvani AP. Dynamic models of infectious disease transmission in prisons and the general population. Epidemiol Rev. 2018;40(1):40–57.CrossRefPubMedPubMedCentral
58.
He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164(2):84–92.CrossRefPubMed
59.
Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology. 2008;48(5):1387–95.CrossRefPubMed
60.
Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8):546–53.CrossRefPubMedPubMedCentral
61.
Chhatwal J, Samur S, Li K, He T, Llerena S, Cobo C, et al. Improved health outcomes from hepatitis C treatment scale-up in Spain’s prisons: a cost-effectiveness study. J Hepatol. 2018;68:S151.CrossRef
62.
Munang M, Smit E, Barnett T, Atherton C, Tahir M, Atabani SF. Outcomes and costs of single-step hepatitis C testing in primary care, Birmingham, United Kingdom. Public health. 2018;166:40–4.CrossRef
63.
Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature. Int J Drug Policy. 2015;26(11):1050–5.CrossRefPubMed
64.
EMCDDA. European Monitoring Centre for Drugs and Drug Addiction Prisons and drugs in Europe: the problem and responses Lisbon. EMCDDA. 2012.
65.
Sander G, Murphy F. The furthest left behind: the urgent need to scale up harm reduction in prisons. Int J Prison Health. 2017;13(3–4):185–91.CrossRefPubMed
66.
Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment--extension for community healthcare outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52(3):1124–33.CrossRefPubMedPubMedCentral
67.
Thornton PSM, Arora S. Treatment of chronic hepatitis C virus (HCV) with direct acting antivirals in the New Mexico state prison system using the ECHO model. J Hepatol. 2017;66(1):S1–S876.CrossRef
68.
Gonzalez JC, Ayesa R, Setién E, Iruzubieta P, Estébanez Á, Crespo-Facorro B, et al. Direct acting antiviral treatment improves hepatitis C-related neurocognitive impaiment. J Hepatol. 2018;68:S271.CrossRef
69.
Llerena S, Mateo M, Cobo C, Blasco A, Cabezas J, Lázaro P, et al. Efficiency of a telemedicine program in the management of hepatitis C in inmates. Hepatology. 2018;68(S1):1–183.
Metadata
Title
HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?
Authors
Javier Crespo
Susana Llerena
Carmen Cobo
Joaquin Cabezas
Antonio Cuadrado
Publication date
01-06-2019
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2019
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-019-00472-2

Other articles of this Issue 2/2019

Current Hepatology Reports 2/2019 Go to the issue

Hepatitis C (H Vargas and S Flamm, Section Editors)

Acute HCV Treatment: What Should We Do in the DAA Era?

Hepatitis C (H Vargas and S Flamm, Section Editors)

Testing for Hepatitis C in Pregnancy: the Time Has Come for Routine Rather than Risk-Based

Hepatitis C (H Vargas and S Flamm, Section Editors)

Hepatitis C-Positive Organs for Liver and Kidney Transplantation—Emerging Data and Current Management Strategies

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Patient Selection in Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites and Associated Conditions

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits